BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 11004817)

  • 1. [Long-term maintenance treatment of reflux esophagitis resistant to H2-RA with PPI (lansoprazole)].
    Endo M; Sugihara K
    Nihon Rinsho; 2000 Sep; 58(9):1865-70. PubMed ID: 11004817
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lansoprazole prevents recurrence of erosive reflux esophagitis previously resistant to H2-RA therapy. The Lansoprazole Maintenance Study Group.
    Sontag SJ; Kogut DG; Fleischmann R; Campbell DR; Richter J; Haber M
    Am J Gastroenterol; 1996 Sep; 91(9):1758-65. PubMed ID: 8792694
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lansoprazole heals erosive reflux esophagitis resistant to histamine H2-receptor antagonist therapy.
    Sontag SJ; Kogut DG; Fleischmann R; Campbell DR; Richter J; Robinson M; McFarland M; Sabesin S; Lehman GA; Castell D
    Am J Gastroenterol; 1997 Mar; 92(3):429-37. PubMed ID: 9068463
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of reflux esophagitis resistant to H2-receptor antagonists with lansoprazole, a new H+/K(+)-ATPase inhibitor: a controlled, double-blind study. Lansoprazole Study Group.
    Feldman M; Harford WV; Fisher RS; Sampliner RE; Murray SB; Greski-Rose PA; Jennings DE
    Am J Gastroenterol; 1993 Aug; 88(8):1212-7. PubMed ID: 8101695
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Comparison between histamine H2-blocker and proton pump inhibitor on the effects of initial treatment in reflux esophagitis].
    Harasawa S
    Nihon Rinsho; 2000 Sep; 58(9):1847-52. PubMed ID: 11004814
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lansoprazole: a comprehensive review.
    Zimmermann AE; Katona BG
    Pharmacotherapy; 1997; 17(2):308-26. PubMed ID: 9085323
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Lansoprazol].
    Ponce J; Nos P
    Gastroenterol Hepatol; 1995 Feb; 18(2):101-9. PubMed ID: 7621274
    [No Abstract]   [Full Text] [Related]  

  • 8. [Cost-effectiveness of the treatment of reflux esophagitis: proton pump inhibitor versus histamine-2-receptor antagonist].
    Habu Y; Oyasu K; Wakamatsu T; Sumitomo Y; Kiyota K; Inokuchi H; Kawai K
    Nihon Rinsho; 2000 Sep; 58(9):1881-5. PubMed ID: 11004820
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Meta-analysis of randomized clinical trials comparing lansoprazole with ranitidine or famotidine in the treatment of acute duodenal ulcer.
    Poynard T; Lemaire M; Agostini H
    Eur J Gastroenterol Hepatol; 1995 Jul; 7(7):661-5. PubMed ID: 8590162
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of lansoprazole in the treatment of erosive reflux esophagitis. The Lansoprazole Group.
    Castell DO; Richter JE; Robinson M; Sontag SJ; Haber MM
    Am J Gastroenterol; 1996 Sep; 91(9):1749-57. PubMed ID: 8792693
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Double-blind controlled-clinical trials of lansoprazole in the treatment of peptic ulcer].
    Ogawa N
    Nihon Rinsho; 1992 Jan; 50(1):68-73. PubMed ID: 1347332
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proton pump inhibitors or histamine-2 receptor antagonists for the prevention of recurrences of erosive reflux esophagitis: a cost-effectiveness analysis.
    Harris RA; Kuppermann M; Richter JE
    Am J Gastroenterol; 1997 Dec; 92(12):2179-87. PubMed ID: 9399748
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A placebo-controlled dose-ranging study of lansoprazole in the management of reflux esophagitis.
    Earnest DL; Dorsch E; Jones J; Jennings DE; Greski-Rose PA
    Am J Gastroenterol; 1998 Feb; 93(2):238-43. PubMed ID: 9468251
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinical effect of proton pump inhibitors on reflux esophagitis].
    Sekiguchi T; Horikoshi T; Nishioka T; Kusano M
    Nihon Rinsho; 1992 Jan; 50(1):131-7. PubMed ID: 1311780
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proton pump inhibitors in acute healing and maintenance of erosive or worse esophagitis: a systematic overview.
    Chiba N
    Can J Gastroenterol; 1997 Sep; 11 Suppl B():66B-73B. PubMed ID: 9347181
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management of symptoms in step-down therapy of gastroesophageal reflux disease.
    Mine S; Iida T; Tabata T; Kishikawa H; Tanaka Y
    J Gastroenterol Hepatol; 2005 Sep; 20(9):1365-70. PubMed ID: 16105122
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Daily low-dose versus alternate day full-dose lansoprazole in the maintenance treatment of reflux esophagitis.
    Baldi F; Morselli-Labate AM; Cappiello R; Ghersi S;
    Am J Gastroenterol; 2002 Jun; 97(6):1357-64. PubMed ID: 12094850
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lansoprazole versus omeprazole in the treatment of reflux esophagitis.
    Vcev A; Stimac D; Vceva A; Rubinić M; Ivandić A; Ivanis N; Horvat D; Volarić M; Karner I
    Acta Med Croatica; 1997; 51(3):171-4. PubMed ID: 9248117
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Omeprazole versus high-dose ranitidine in mild gastroesophageal reflux disease: short- and long-term treatment. The Dutch Reflux Study Group.
    Festen HP; Schenk E; Tan G; Snel P; Nelis F
    Am J Gastroenterol; 1999 Apr; 94(4):931-6. PubMed ID: 10201459
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preventive therapy for non-steroidal anti-inflammatory drug-induced ulcers in Japanese patients with rheumatoid arthritis: the current situation and a prospective controlled-study of the preventive effects of lansoprazole or famotidine.
    Miyake K; Ueki N; Suzuki K; Shinji Y; Kusunoki M; Hiratsuka T; Nishigaki H; Tatsuguchi A; Futagami S; Wada K; Tsukui T; Nakajima A; Yoshino S; Sakamoto C
    Aliment Pharmacol Ther; 2005 Jun; 21 Suppl 2():67-72. PubMed ID: 15943850
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.